These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 9533455)
1. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. Boswell FJ; Andrews JM; Wise R J Antimicrob Chemother; 1998 Feb; 41(2):149-53. PubMed ID: 9533455 [TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic properties of HMR 3004, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time kill kinetics and postantibiotic effect. Boswell FJ; Andrews JM; Wise R Clin Microbiol Infect; 1998 Apr; 4(4):186-192. PubMed ID: 11864324 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect. Boswell FJ; Andrews JM; Wise R J Antimicrob Chemother; 1997 Mar; 39(3):415-8. PubMed ID: 9096193 [TBL] [Abstract][Full Text] [Related]
4. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Biedenbach DJ; Barrett MS; Jones RN Diagn Microbiol Infect Dis; 1998 Jun; 31(2):349-53. PubMed ID: 9635909 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Hoban DJ; Zhanel GG; Karlowsky JA Diagn Microbiol Infect Dis; 1999 Sep; 35(1):37-44. PubMed ID: 10529880 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens. Odenholt I; Löwdin E; Cars O Antimicrob Agents Chemother; 2001 Jan; 45(1):23-9. PubMed ID: 11120939 [TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci. Wootton M; Bowker KE; Janowska A; Holt HA; MacGowan AP J Antimicrob Chemother; 1999 Oct; 44(4):445-53. PubMed ID: 10588304 [TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics. Bonnefoy A; Le Priol P J Antimicrob Chemother; 2001 Apr; 47(4):471-3. PubMed ID: 11266424 [TBL] [Abstract][Full Text] [Related]
9. In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides. Abbanat D; Webb G; Foleno B; Li Y; Macielag M; Montenegro D; Wira E; Bush K Antimicrob Agents Chemother; 2005 Jan; 49(1):309-15. PubMed ID: 15616310 [TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. Walsh F; Carnegy F; Willcock J; Amyes S J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640 [TBL] [Abstract][Full Text] [Related]
11. Postantibiotic effect and postantibiotic sub-mic effect of dirithromycin and erythromycin against respiratory tract pathogenic bacteria. Dornbusch K; Olofsson C; Holm S APMIS; 1999 May; 107(5):505-13. PubMed ID: 10335955 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus. Nord CE; Lindmark A; Persson I J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369 [No Abstract] [Full Text] [Related]
13. In vitro activities of macrolides against gram-positive aerobes, Haemophilus influenzae, Moraxella catarrhalis and Bacteroides fragilis in Taiwan. Wang FD; Liu IM; Liu CY Zhonghua Yi Xue Za Zhi (Taipei); 1999 Apr; 62(4):230-5. PubMed ID: 10367484 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. Barry AL; Fuchs PC; Brown SD Eur J Clin Microbiol Infect Dis; 1997 Oct; 16(10):767-9. PubMed ID: 9405952 [TBL] [Abstract][Full Text] [Related]
15. Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens. Drago L; De Vecchi E; Nicola L; Legnani D; Gismondo MR APMIS; 2005 Oct; 113(10):655-63. PubMed ID: 16309423 [TBL] [Abstract][Full Text] [Related]
16. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. Felmingham D J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493 [TBL] [Abstract][Full Text] [Related]
17. Microbiological profile of telithromycin, the first ketolide antimicrobial. Felmingham D Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558 [TBL] [Abstract][Full Text] [Related]